WallStSmart

Dominion Energy Inc (D)vsNovo Nordisk A/S (NVO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 1779% more annual revenue ($327.80B vs $17.45B). NVO leads profitability with a 37.2% profit margin vs 16.9%. D appears more attractively valued with a PEG of 2.78. NVO earns a higher WallStSmart Score of 74/100 (B).

D

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 7.5Value: 4.0Quality: 3.8
Piotroski: 4/9Altman Z: 0.59

NVO

Strong Buy

74

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.7Quality: 4.8
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DOvervalued (-14.2%)

Margin of Safety

-14.2%

Fair Value

$56.60

Current Price

$61.89

$5.29 premium

UndervaluedFair: $56.60Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

D4 strengths · Avg: 8.3/10
Market CapQuality
$54.18B9/10

Large-cap with strong market position

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Operating MarginProfitability
28.7%8/10

Strong operational efficiency at 28.7%

Revenue GrowthGrowth
23.1%8/10

Revenue surging 23.1% year-over-year

NVO6 strengths · Avg: 10.0/10
Market CapQuality
$202.85B10/10

Mega-cap, among the largest globally

P/E RatioValuation
10.6x10/10

Attractively priced relative to earnings

Return on EquityProfitability
71.4%10/10

Every $100 of equity generates 71 in profit

Profit MarginProfitability
37.2%10/10

Keeps 37 of every $100 in revenue as profit

Operating MarginProfitability
61.6%10/10

Strong operational efficiency at 61.6%

EPS GrowthGrowth
67.1%10/10

Earnings expanding 67.1% YoY

Areas to Watch

D4 concerns · Avg: 2.0/10
PEG RatioValuation
2.782/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.2%2/10

Earnings declined 10.2%

Free Cash FlowQuality
$-2.15B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.592/10

Distress zone — elevated risk

NVO2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.882/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : D

The strongest argument for D centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 28.7%. Revenue growth of 23.1% demonstrates continued momentum.

Bull Case : NVO

The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 37.2% and operating margin at 61.6%. Revenue growth of 24.0% demonstrates continued momentum.

Bear Case : D

The primary concerns for D are PEG Ratio, EPS Growth, Free Cash Flow.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

D carries more volatility with a beta of 0.64 — expect wider price swings.

NVO is growing revenue faster at 24.0% — sustainability is the question.

NVO generates stronger free cash flow (12.0B), providing more financial flexibility.

Monitor UTILITIES - REGULATED ELECTRIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVO scores higher overall (74/100 vs 63/100), backed by strong 37.2% margins and 24.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Dominion Energy Inc

UTILITIES · UTILITIES - REGULATED ELECTRIC · USA

Dominion Energy, Inc., commonly referred to as Dominion, is an American power and energy company headquartered in Richmond, Virginia that supplies electricity in parts of Virginia, North Carolina, and South Carolina and supplies natural gas to parts of Utah, West Virginia, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia. Dominion also has generation facilities in Indiana, Illinois, Connecticut, and Rhode Island.

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?